Urology Associates, P.C.
Urology Associates, P.C.
Nashville, Tennessee, United States12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-09-28 | NCT07206225 | |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Recruiting | Phase 3 | 2026-09-25 | NCT06545955 | |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07028853 | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, neoplasm, superficial urinary bladder carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-07 | NCT04752722 | |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 | 2026-08-06 | NCT05483868 | |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Cancer of Urinary Tract, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 3 | 2026-07-01 | NCT06111235 | |
| Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hematuria, Hemorrhage, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Not stated | 2026-06-29 | NCT07673016 | |
| 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-05-14 | NCT06970847 | |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Not stated | 2026-05-12 | NCT03933826 | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 3 | 2026-05-11 | NCT05243550 | |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | Recruiting | Phase 2 | 2026-05-08 | NCT04986423 | |
| ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT06800963 |